Roche Will Miss Goal of Filing RNAi Rx IND This Year, Tekmira Exec Says | GenomeWeb

Roche will not meet its previously disclosed goal of filing an investigational new drug application for an siRNA-based drug candidate in 2010, an official from partner Tekmira Pharmaceuticals disclosed last week.

As reported by Gene Silencing News in 2009, Roche had been expecting to file the IND on what would be its first RNAi drug sometime this year (GSN 10/1/2009).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.